Inside Stayble: November 2020
In the November 2020 edition, CEO Andreas Gerward, explains the clinical phase IIb study with STA363 more in-depth and provides an overview of the company’s current affairs.
Inside Stayble is a new communication channel aiming to provide shareholders with monthly updates about Stayble Therapeutics and its clinical development program for STA363 in chronic low back pain.
Stayble Therapeutics is listed on Nasdaq First North in Sweden (STABL).
Read more at staybletherapeutics.com.